News

Captor Therapeutics reports Q3 2022 results and provides business update. Lead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical

Ono Pharmaceutical and Captor Therapeutics announce drug discovery collaboration to develop small molecule protein degraders for the treatment of neurodegenerative diseases

Captor Therapeutics announces participation in upcoming scientific, investor, and partnering conferences in October 2022

Captor Therapeutics' first half of 2022 marked by significant progress in R&D and preparations for the commencement of clinical trials

Captor Therapeutics nominates the molecular glue CPT-6281 as drug candidate to enter CTA/IND-enabling studies for the treatment of hepatocellular carcinoma

Captor Therapeutics to attend Wedbush PacGrow Healthcare Conference 2022

Zaproszenie na Walne Zgromadzenie

Captor Therapeutics Q1 2022 report: company continues to generate exciting data on lead projects (CT-01, CT-02, CT-03), maintains strong financial position

Captor Therapeutics to host R&D Day on May 18, 2022

Captor Therapeutics has released its 2021 report. Recent quarterly results have seen significant R&D progress; The Company has sufficient funds for further research and is meeting expenditures on schedule